A5062088249- Ocular Oncology and Treatments
- Cutaneous Melanoma Detection and Management
- Retinal Development and Disorders
- Glaucoma and retinal disorders
- CNS Lymphoma Diagnosis and Treatment
- Nonmelanoma Skin Cancer Studies
- Retinal Diseases and Treatments
- Corneal Surgery and Treatments
- Ocular Infections and Treatments
- Lymphoma Diagnosis and Treatment
- Brain Metastases and Treatment
- Immunotherapy and Immune Responses
- Cancer-related Molecular Pathways
- Cancer and Skin Lesions
- melanin and skin pigmentation
- Glioma Diagnosis and Treatment
- Retinal and Macular Surgery
- Vascular Tumors and Angiosarcomas
- Ocular Diseases and Behçet’s Syndrome
- Neurofibromatosis and Schwannoma Cases
- History of Medicine Studies
- Ocular Disorders and Treatments
- Tuberous Sclerosis Complex Research
- Intraocular Surgery and Lenses
- Virus-based gene therapy research
Cleveland Eye Clinic
2016-2025
Cleveland Clinic
2016-2025
Government Medical College
2025
UCLA Health
2025
Louisiana State University Health Sciences Center Shreveport
2024
Vardhman Mahavir Medical College & Safdarjung Hospital
2023-2024
Mysore Medical College
2024
Ophthalmology Associates (United States)
2024
Prevent Blindness
2020-2023
M.J.P. Rohilkhand University
2019-2023
BackgroundTuberous sclerosis complex is highly variable in clinical presentation and findings. Disease manifestations continue to develop over the lifetime of an affected individual. Accurate diagnosis fundamental implementation appropriate medical surveillance treatment. Although significant advances have been made past 15 years understanding treatment tuberous complex, current diagnostic criteria not critically evaluated or updated since last consensus conference 1998.MethodsThe 2012...
Tuberous sclerosis complex is a genetic disorder affecting every organ system, but disease manifestations vary significantly among affected individuals. The diverse and varied presentations progression can be life-threatening with significant impact on cost quality of life. Current surveillance management practices are highly variable region country, reflective the fact that last consensus recommendations occurred in 1998 an updated, comprehensive standard lacking incorporates latest...
The purpose of this study was to determine the age-adjusted incidence retinoblastoma in USA over a 30-year period from 1975 2004 using review existing databases.Six hundred and fifty-eight patients with (International Classification Oncology (ICDO-3) codes C69.2 (retina) C69.9 (eye, NOS)) were derived Surveillance, Epidemiology, End Results (SEER) program database 2004. Nine historical SEER registries utilised. significance trend rate determined chi(2) test, 95% CIs calculated. stratified...
To analyze trends in incidence, treatment, and survival of uveal melanoma the United States from 1973 to 2013 using Surveillance, Epidemiology, End Results database.Patients were identified International Classification Disease for Oncology codes: C69.3 (choroid), C69.4 (ciliary body iris), C69.2 (retina). Trends age-adjusted treatment (surgery or radiation), 5-year relative calculated.There 4,999 cases melanoma. The majority (97.8%) reported by hospital inpatient/outpatient clinics....
The purpose of this study was to determine the survival retinoblastoma in USA over a 30-year period from 1975 2004 using systematic review existing databases.Nine hundred and ninety-two cases (International Classification Oncology (ICDO-3) codes C69.2 (retina) C69.9 (eye, NOS)) were derived Surveillance, Epidemiology End Results (SEER) program database 2004. All 17 current SEER registries utilised allow for optimal patient volume statistical analysis. Survival rates calculated by...
Uveal melanoma is the most common primary intraocular malignant tumour, with an annual incidence of approximately six cases per million year. Approximately 40% patients posterior uveal develop metastatic to liver within 10 years after initial diagnosis. Despite high accuracy diagnosis and availability various methods treatment; mortality due has remained unchanged. The prognosis in depends on clinical, histopathological cytological factors. Clinical factors that relate include location,...
Although an accurate uveal melanoma staging system is needed to improve research and patient care, the evaluation of eye cancer systems requires international multicenter data sharing acquire a statistically significant analysis.To assess mortality outcomes associated with according 7th edition American Joint Committee on Cancer's AJCC Cancer Staging Manual.A committee was formed create patient-specific fields for patients melanoma. Ten subspecialty ophthalmic oncology centers from 4...
PurposeTo assess of the effect local recurrence uveal melanoma on metastasis using a multicenter international tumor registry.DesignRetrospective study an online registry.ParticipantsPatients with diagnosed between 2001 and 2011.MethodsA committee was formed to create patient-specific data fields. Ten subspecialty ophthalmic oncology centers from 4 continents shared data. Patient selection criteria included diagnosis adequate records allow staging by American Joint Committee Cancer (AJCC)...
<h3>Purpose</h3> To report outcomes and complications of fine-needle aspiration biopsy (FNAB) uveal melanoma performed for diagnostic prognostic purposes. <h3>Methods</h3> Prospective interventional case series 150 consecutive patients with a clinical diagnosis melanoma. The FNAB approach (transcorneal (TCO), transscleral (TSC) transvitreal (TVT) was primarily determined by the location tumour. using 25-gauge needle previously published technique. Prognostication done fluorescent in situ...
Uveal melanoma (UM) is the most common intraocular malignancy in adults. In contrast to cutaneous (CM), there no standard therapy, and efficacy safety of dual checkpoint blockade with nivolumab ipilimumab not well defined.